We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Organ failure

7 August 2017 By Olaf Storbeck

Kidney dialysis group Fresenius Medical Care is forking out $2 bln in cash for loss-making rival NxStage. The German group enjoys a remarkably low cost of capital. But even if it delivers ambitious cost savings and the American group keeps getting better, returns will fall short.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)